Liquid chromatography–tandem mass spectrometry assay for the simultaneous determination of apalutamide and its active metabolite N-desmethyl apalutamide, and its application in real-world patients with castration-resistant prostate cancer
Therapeutic drug monitoring can help evaluate the individual differences between patients taking apalutamide. A dose of 180 mg could reduce the baseline PSA level significantly (p < 0.05), and the incidence of skin rash was less compared to that of a dose of 240 mg.
Authors
- Yuxuan Zhu (ORCID: https://orcid.org/0000-0003-2203-4765)
- Wenqiang Cheng
- Lijuan Zhang (ORCID: https://orcid.org/0000-0002-3469-9855)
- Lu Chen (ORCID: https://orcid.org/0000-0001-7580-9312)
- Jun Li (ORCID: https://orcid.org/0000-0001-5173-271X)
- Dingyuan Yang
Institutions
- University of Electronic Science and Technology of China (CN)
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
- Chengdu Second People's Hospital (CN)
- Second People’s Hospital of Yibin (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.3389/fphar.2025.1510583
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Department of Science and Technology of Sichuan Province